PPARG and cancer: Therefore, clinical trials withcombination therapies were initiated to exploit PPARγ activation and simultaneousblockage of the promitotic and proinflammatory COX1/2-mediated eicosanoidproduction, which contributes to nongenomic signaling in cancer tissues (Figure 2).